Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs.
A method for determination of the atypical neuroleptic drug olanzapine in serum was developed. After a single-step liquid-liquid extraction, the compound was separated from other constituents on a normal-phase silica gel column using a buffer-methanol mobile phase and measured by UV absorption at 270 nm. Addition of 0.25% ascorbic acid to serum protects olanzapine against oxidation during extraction and stabilizes the easily oxidised compound during storage. Inter-day variation was <8% at serum levels found in olanzapine treated patients. Analytical interference from coadministered psychoactive drugs and their metabolites were studied. Only risperidone, also a relatively newly developed antipsychotic drug, interfered, but the most commonly used antidepressants and traditional antipsychotics and their metabolites did not interfere.
Olesen
O V
OV
Institute for Basic Research in Psychiatry, Department of Biological Psychiatry, Psychiatric Hospital, Risskov, Denmark.
Linnet
K
K
D014150:Antipsychotic Agents / Q000097:blood* / Q000737:chemistry; D016477:Artifacts; D001205:Ascorbic Acid / Q000737:chemistry; D001569:Benzodiazepines; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D000077152:Olanzapine; D010084:Oxidation-Reduction; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine; D001205:Ascorbic Acid